In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
- Astellas Gets Rights to Urology Drug Rosiptor in Asia-Pacific Region
May 11, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- YL Biologics Files Enbrel Biosimilar in Japan
May 11, 2018
- MSD Japan Seeks Adjuvant Melanoma Nod for Keytruda
May 11, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Shire Buyout a Must for Takeda’s Leap in Global Arena: Board Chair
May 10, 2018
- Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
May 10, 2018
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Takeda’s Shire Deal Inspiring for Japan Industry Peers: Mitsubishi Tanabe Chief
May 10, 2018
- Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
- AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
May 10, 2018
- Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
May 10, 2018
- Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
May 9, 2018
- Daiichi Sankyo, Kaketsuken Terminate Vaccine Sales Partnership
May 9, 2018
- US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
May 9, 2018
- Kissei Mulls Over Urief AG Launch
May 9, 2018
- MHLW Official Hails Takeda’s Shire Takeover
May 9, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…